CoChat

D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization

Open access
Weissman, Drew, Alameh, Mohamad-Gabriel, de Silva, Thushan, Collini, Paul, Hornsby, Hailey, Brown, Rebecca, LaBranche, Celia C., Edwards, Robert J, Sutherland, Laura, Santra, Sampa, Mansouri, Katayoun, Gobeil, Sophie, McDanal, Charlene, Pardi, Norbert, Hengartner, Nick, Lin, Paulo J.C., Tam, Ying, Shaw, Pamela A., Lewis, Mark G., Boesler, Carsten, Şahin, Uğur, Acharya, Priyamvada, Haynes, Barton F., Korber, Bette, Montefiori, David C. · 2020 · medRxiv

Preprint — published as 10.1016/j.chom.2020.11.012 · Paper page

PreprintCited by 71

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Summary: The SARS-CoV-2 Spike protein acquired a D614G mutation early in the COVID-19 pandemic that appears to confer on the virus greater infectivity and is now the globally dominant form of the virus. Certain of the current vaccines entering phase 3 trials are based on the original D614 form of Spike with the goal of eliciting protective neutralizing antibodies. To determine whether D614G mediates neutralization-escape that could compromise vaccine efficacy, sera from Spike-immunized mice, nonhuman primates and humans were evaluated for neutralization of pseudoviruses bearing either D614 or G614 Spike on their surface. In all cases, the G614 pseudovirus was moderately more susceptible to neutralization. The G614 pseudovirus also was more susceptible to neutralization by monoclonal antibodies against the receptor binding domain and by convalescent sera from people known to be infected with either the D614 or G614 form of the virus. These results indicate that a gain in infectivity provided by D614G came at the cost of making the virus more vulnerable to neutralizing antibodies, and that the mutation is not expected to be an obstacle for current vaccine development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2020.07.22.20159905

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 40

  1. Alameh, M.G. , Weissman, D. , and Pardi, N. (2020). Messenger RNA-Based Vaccines Against Infectious Diseases. Current topics in microbiology and immunology. · DOI · Paper page
  2. 2019, A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA, Molecular therapy Nucleic acids, 15, 26, 10.1016/j.omtn.2019.02.018 · DOI · Paper page
  3. 10.4103/ijmr.IJMR_1125_20 · DOI
  4. Brouwer, P.J.M. , Caniels, T.G. , van der Straten, K. , Snitselaar, J.L. , Aldon, Y. , Bangaru, S. , Torres, J.L. , Okba, N.M.A. , Claireaux, M. , Kerster, G., et al. (2020). Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. · DOI · Paper page
  5. Chi, X. , Yan, R. , Zhang, J. , Zhang, G. , Zhang, Y. , Hao, M. , Zhang, Z. , Fan, P. , Dong, Y. , Yang, Y. , et al. (2020). A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. · DOI · Paper page
  6. Corbett, K.S. , Edwards, D.K. , Leist, S.R. , Abiona, O.M. , Boyoglu-Barnum, S. , Gillespie, R.A. , Himansu, S. , Schafer, A. , Ziwawo, C.T. , DiPiazza, A.T. , et al. (2020). SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. · DOI · Paper page
  7. 2020, SARS-CoV-2 genomic surveillance in Taiwan revealed novel ORF8-deletion mutant and clade possibly associated with infections in Middle East, Emerging microbes & infections, 9, 1457, 10.1080/22221751.2020.1782271 · DOI · Paper page
  8. 10.1016/j.jmb.2004.02.020 · DOI
  9. Henderson, R. , Edwards, R.J. , Mansouri, K. , Janowska, K. , Stalls, V. , Gobeil, S.M.C. , Kopp, M. , Li, D. , Parks, R. , Hsu, A.L. , et al. (2020). Controlling the SARS-CoV-2 spike glycoprotein conformation. Nat Struct Mol Biol. · DOI · Paper page
  10. 2020, Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide, Scientific reports, 10, 14031, 10.1038/s41598-020-70827-z · DOI · Paper page
  11. Islam, O.K. , Al-Emran, H.M. , Hasan, M.S. , Anwar, A. , Jahid, M.I.K. , and Hossain, M.A. (2020). Emergence of European and North American mutant variants of SARS-CoV-2 in South-East Asia. Transboundary and emerging diseases. · DOI
  12. 10.1101/2020.03.21.990770 · DOI
  13. 10.1038/nature17200 · DOI · Paper page
  14. 2018, Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis, Scientific reports, 8, 15701, 10.1038/s41598-018-34171-7 · DOI · Paper page
  15. Korber, B. , Fischer, W.M. , Gnanakaran, S. , Yoon, H. , Theiler, J. , Abfalterer, W. , Foley, B. , Giorgi, E.E. , Bhattacharya, T. , Parker, M.D. , et al. (2020a). Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. bioRxiv: the preprint server for biology 04.29.069054. · DOI
  16. 10.1016/j.cell.2020.06.043 · DOI · Paper page
  17. 2020, Variant analysis of SARS-CoV-2 genomes, Bulletin of the World Health Organization, 98, 495, 10.2471/BLT.20.253591 · DOI · Paper page
  18. Koyama, T. , Weeraratne, D. , Snowdon, J.L. , and Parida, L. (2020b). Emergence of Drift Variants That May Affect COVID-19 Vaccine Development and Antibody Treatment. Pathogens (Basel, Switzerland) 9. · doi:10.20944/preprints202004.0024.v1
  19. Laczko, D. , Hogan, M.J. , Toulmin, S.A. , Hicks, P. , Lederer, K. , Gaudette, B.T. , Castano, D. , Amanat, F. , Muramatsu, H. , Oguin, T.H. , 3rd, et al. (2020). A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice. Immunity. · DOI · Paper page
  20. 2013, Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA, Nanomedicine: nanotechnology, biology, and medicine, 9, 233, 10.1016/j.nano.2012.05.019 · DOI
  21. Liu, L. , Wang, P. , Nair, M.S. , Yu, J. , Huang, Y. , Rapp, M.A. , Wang, Q. , Luo, Y. , Sahi, V. , Figueroa, A. , et al. (2020). Potent Neutralizing Monoclonal Antibodies Directed to Multiple Epitopes on the SARS-CoV-2 Spike. bioRxiv: the preprint server for biology.
  22. 2020, Developing Covid-19 Vaccines at Pandemic Speed, The New England journal of medicine, 382, 1969, 10.1056/NEJMp2005630 · DOI · Paper page
  23. Mansbach, R.A. , Chakraborty, S. , Nguyen, K. , Montefiori, D. , Korber, B. , and Gnanakaran, S. (2020). The SARS-CoV-2 Spike Variant D614G Favors an Open Conformational State. bioRxiv: the preprint server for biology.
  24. 10.1097/COH.0000000000000363 · DOI
  25. 2020, Geographic and Genomic Distribution of SARS-CoV-2 Mutations, Frontiers in microbiology, 11, 1800, 10.3389/fmicb.2020.01800 · DOI · Paper page
  26. Mulligan, M.J. , Lyke, K.E. , Kitchin, N. , Absalon, J. , Gurtman, A. , Lockhart, S. , Neuzil, K. , Raabe, V. , Bailey, R. , Swanson, K.A. , et al. (2020). Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. bioRxiv: the preprint server for biology 2020.06.20.159715.
  27. 10.1126/science.272.5259.263 · DOI · Paper page
  28. 2015, Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes, Journal of controlled release: official journal of the Controlled Release Society, 217, 345, 10.1016/j.jconrel.2015.08.007 · DOI · Paper page
  29. 2020, Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody, Nature, 583, 290, 10.1038/s41586-020-2349-y · DOI · Paper page
  30. Sahin, U. , et al., (2020). Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine. medRxiv: the preprint server for health sciences, https://doi.org/10.1101/2020.1107.1117.20140533. · doi:10.1101/2020.1107.1117.20140533
  31. 10.1016/bs.mie.2016.04.012 · DOI · Paper page
  32. Schmidt, F. , Weisblum, Y. , Muecksch, F. , Hoffmann, H.H. , Michailidis, E. , Lorenzi, J.C.C. , Mendoza, P. , Rutkowska, M. , Bednarski, E. , Gaebler, C. , et al. (2020). Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. The Journal of experimental medicine 217. · DOI · Paper page
  33. Shi, R. , Shan, C. , Duan, X. , Chen, Z. , Liu, P. , Song, J. , Song, T. , Bi, X. , Han, C. , Wu, L. , et al. (2020). A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. · DOI · Paper page
  34. 2006, Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants, PLoS medicine, 3, e237, 10.1371/journal.pmed.0030237 · DOI · Paper page
  35. Wec, A.Z. , Wrapp, D. , Herbert, A.S. , Maurer, D.P. , Haslwanter, D. , Sakharkar, M. , Jangra, R.K. , Dieterle, M.E. , Lilov, A. , Huang, D. , et al. (2020). Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science. · DOI · Paper page
  36. 10.1126/science.abb2507 · DOI · Paper page
  37. 10.1126/science.abc2241 · DOI · Paper page
  38. 10.1126/science.abb7269 · DOI · Paper page
  39. Yurkovetskiy, L. , Wang, X. , Pascal, K.E. , Tomkins-Tinch, C. , Nyalile, T. , Wang, Y. , Baum, A. , Diehl, W.E. , Dauphin, A. , Carbone, C. , et al. (2020). Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant. bioRxiv: the preprint server for biology July 16, 2020.
  40. Zhang, L. , Jackson, C.B. , Mou, H. , Ojha, A. , Rangarajan, E.S. , Izard, T. , Farzan, M. , and Choe, H. (2020). The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. bioRxiv: the preprint server for biology.

Cited by

See all 71

Metadata

Authors
Weissman, D., Alameh, M.-G., de Silva, T., Collini, P., Hornsby, H., Brown, R., LaBranche, C. C., Edwards, R. J., Sutherland, L., Santra, S., Mansouri, K., Gobeil, S., McDanal, C., Pardi, N., Hengartner, N., Lin, P. J. C., Tam, Y., Shaw, P. A., Lewis, M. G., Boesler, C., Şahin, U., Acharya, P., Haynes, B. F., Korber, B., & Montefiori, D. C.
Venue
medRxiv
Publisher
openRxiv
Published
2020-07-24
OpenAlex
W3045042666
Cited by
71
References
7
Type
posted content
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.